

New Psychoactive Substance-Global Market Status & Trend Report 2016-2026 Top 20 Countries Data

<https://marketpublishers.com/r/N37B07BDA2CDEN.html>

Date: December 2021

Pages: 141

Price: US\$ 3,680.00 (Single User License)

ID: N37B07BDA2CDEN

Abstracts

Report Summary

New Psychoactive Substance-Global Market Status & Trend Report 2016-2026 Top 20 Countries Data offers a comprehensive analysis on New Psychoactive Substance industry, standing on the readers' perspective, delivering detailed market data in Global major 20 countries and penetrating insights. No matter the client is industry insider, potential entrant or investor, the report will provides useful data and information. Key questions answered by this report include:

Worldwide and Top 20 Countries Market Size of New Psychoactive Substance 2016-2021, and development forecast 2022-2026

Main manufacturers/suppliers of New Psychoactive Substance worldwide and market share by regions, with company and product introduction, position in the New Psychoactive Substance market

Market status and development trend of New Psychoactive Substance by types and applications

Cost and profit status of New Psychoactive Substance, and marketing status

Market growth drivers and challenges Since the COVID-19 virus outbreak in December 2019, the disease has spread to almost 100 countries around the globe with the World Health Organization declaring it a public health emergency. The global impacts of the coronavirus disease 2019 (COVID-19) are already starting to be felt, and will significantly affect the Ammonium New Psychoactive Substance market in 2020. COVID-19 can affect the global economy in three main ways: by directly affecting production and demand, by creating supply chain and market disruption, and by its financial impact on firms and financial markets. The outbreak of COVID-19 has brought effects on many aspects, like flight cancellations; travel bans and quarantines;

restaurants closed; all indoor events restricted; over forty countries state of emergency declared; massive slowing of the supply chain; stock market volatility; falling business confidence, growing panic among the population, and uncertainty about future. This report also analyses the impact of Coronavirus COVID-19 on the New Psychoactive Substance industry.

The report segments the global New Psychoactive Substance market as:

Global New Psychoactive Substance Market: Regional Segment Analysis (Regional Production Volume, Consumption Volume, Revenue and Growth Rate 2016-2026):

North America (United States, Canada and Mexico)

Europe (Germany, UK, France, Italy, Russia, Spain and Benelux)

Asia Pacific (China, Japan, India, Southeast Asia and Australia)

Latin America (Brazil, Argentina and Colombia)

Middle East and Africa

Global New Psychoactive Substance Market: Type Segment Analysis (Consumption Volume, Average Price, Revenue, Market Share and Trend 2016-2026):

Stimulants

Cannabinoids

Hallucinogens

Depressants

Global New Psychoactive Substance Market: Application Segment Analysis (Consumption Volume and Market Share 2016-2026; Downstream Customers and Market Analysis)

Cancer

Neuropathic Disorders

Spasticity

Others

Global New Psychoactive Substance Market: Manufacturers Segment Analysis (Company and Product introduction, New Psychoactive Substance Sales Volume, Revenue, Price and Gross Margin):

Zynerba Pharmaceuticals

GW Pharmaceuticals

Teewinot Life Sciences

AusCann

Cannabics Pharmaceuticals

Tilray
Cyrelia
Anandia Laboratories
InMed Pharmaceuticals
Renew Biopharma
Cronos Group
ICC International Cannabis
Biotii Technologies

In a word, the report provides detailed statistics and analysis on the state of the industry; and is a valuable source of guidance and direction for companies and individuals interested in the market.

Contents

CHAPTER 1 OVERVIEW OF NEW PSYCHOACTIVE SUBSTANCE

- 1.1 Definition of New Psychoactive Substance in This Report
- 1.2 Commercial Types of New Psychoactive Substance
 - 1.2.1 Stimulants
 - 1.2.2 Cannabinoids
 - 1.2.3 Hallucinogens
 - 1.2.4 Depressants
- 1.3 Downstream Application of New Psychoactive Substance
 - 1.3.1 Cancer
 - 1.3.2 Neuropathic Disorders
 - 1.3.3 Spasticity
 - 1.3.4 Others
- 1.4 Development History of New Psychoactive Substance
- 1.5 Market Status and Trend of New Psychoactive Substance 2016-2026
 - 1.5.1 Global New Psychoactive Substance Market Status and Trend 2016-2026
 - 1.5.2 Regional New Psychoactive Substance Market Status and Trend 2016-2026

CHAPTER 2 GLOBAL MARKET STATUS AND FORECAST BY REGIONS

- 2.1 Market Development of New Psychoactive Substance 2016-2021
- 2.2 Sales Market of New Psychoactive Substance by Regions
 - 2.2.1 Sales Volume of New Psychoactive Substance by Regions
 - 2.2.2 Sales Value of New Psychoactive Substance by Regions
- 2.3 Production Market of New Psychoactive Substance by Regions
- 2.4 Global Market Forecast of New Psychoactive Substance 2022-2026
 - 2.4.1 Global Market Forecast of New Psychoactive Substance 2022-2026
 - 2.4.2 Market Forecast of New Psychoactive Substance by Regions 2022-2026

CHAPTER 3 GLOBAL MARKET STATUS AND FORECAST BY TYPES

- 3.1 Sales Volume of New Psychoactive Substance by Types
- 3.2 Sales Value of New Psychoactive Substance by Types
- 3.3 Market Forecast of New Psychoactive Substance by Types

CHAPTER 4 GLOBAL MARKET STATUS AND FORECAST BY DOWNSTREAM INDUSTRY

- 4.1 Global Sales Volume of New Psychoactive Substance by Downstream Industry
- 4.2 Global Market Forecast of New Psychoactive Substance by Downstream Industry

CHAPTER 5 NORTH AMERICA MARKET STATUS BY COUNTRIES, TYPE, MANUFACTURERS AND DOWNSTREAM INDUSTRY

- 5.1 North America New Psychoactive Substance Market Status by Countries
 - 5.1.1 North America New Psychoactive Substance Sales by Countries (2016-2021)
 - 5.1.2 North America New Psychoactive Substance Revenue by Countries (2016-2021)
 - 5.1.3 United States New Psychoactive Substance Market Status (2016-2021)
 - 5.1.4 Canada New Psychoactive Substance Market Status (2016-2021)
 - 5.1.5 Mexico New Psychoactive Substance Market Status (2016-2021)
- 5.2 North America New Psychoactive Substance Market Status by Manufacturers
- 5.3 North America New Psychoactive Substance Market Status by Type (2016-2021)
 - 5.3.1 North America New Psychoactive Substance Sales by Type (2016-2021)
 - 5.3.2 North America New Psychoactive Substance Revenue by Type (2016-2021)
- 5.4 North America New Psychoactive Substance Market Status by Downstream Industry (2016-2021)

CHAPTER 6 EUROPE MARKET STATUS BY COUNTRIES, TYPE, MANUFACTURERS AND DOWNSTREAM INDUSTRY

- 6.1 Europe New Psychoactive Substance Market Status by Countries
 - 6.1.1 Europe New Psychoactive Substance Sales by Countries (2016-2021)
 - 6.1.2 Europe New Psychoactive Substance Revenue by Countries (2016-2021)
 - 6.1.3 Germany New Psychoactive Substance Market Status (2016-2021)
 - 6.1.4 UK New Psychoactive Substance Market Status (2016-2021)
 - 6.1.5 France New Psychoactive Substance Market Status (2016-2021)
 - 6.1.6 Italy New Psychoactive Substance Market Status (2016-2021)
 - 6.1.7 Russia New Psychoactive Substance Market Status (2016-2021)
 - 6.1.8 Spain New Psychoactive Substance Market Status (2016-2021)
 - 6.1.9 Benelux New Psychoactive Substance Market Status (2016-2021)
- 6.2 Europe New Psychoactive Substance Market Status by Manufacturers
- 6.3 Europe New Psychoactive Substance Market Status by Type (2016-2021)
 - 6.3.1 Europe New Psychoactive Substance Sales by Type (2016-2021)
 - 6.3.2 Europe New Psychoactive Substance Revenue by Type (2016-2021)
- 6.4 Europe New Psychoactive Substance Market Status by Downstream Industry (2016-2021)

CHAPTER 7 ASIA PACIFIC MARKET STATUS BY COUNTRIES, TYPE, MANUFACTURERS AND DOWNSTREAM INDUSTRY

- 7.1 Asia Pacific New Psychoactive Substance Market Status by Countries
 - 7.1.1 Asia Pacific New Psychoactive Substance Sales by Countries (2016-2021)
 - 7.1.2 Asia Pacific New Psychoactive Substance Revenue by Countries (2016-2021)
 - 7.1.3 China New Psychoactive Substance Market Status (2016-2021)
 - 7.1.4 Japan New Psychoactive Substance Market Status (2016-2021)
 - 7.1.5 India New Psychoactive Substance Market Status (2016-2021)
 - 7.1.6 Southeast Asia New Psychoactive Substance Market Status (2016-2021)
 - 7.1.7 Australia New Psychoactive Substance Market Status (2016-2021)
- 7.2 Asia Pacific New Psychoactive Substance Market Status by Manufacturers
- 7.3 Asia Pacific New Psychoactive Substance Market Status by Type (2016-2021)
 - 7.3.1 Asia Pacific New Psychoactive Substance Sales by Type (2016-2021)
 - 7.3.2 Asia Pacific New Psychoactive Substance Revenue by Type (2016-2021)
- 7.4 Asia Pacific New Psychoactive Substance Market Status by Downstream Industry (2016-2021)

CHAPTER 8 LATIN AMERICA MARKET STATUS BY COUNTRIES, TYPE, MANUFACTURERS AND DOWNSTREAM INDUSTRY

- 8.1 Latin America New Psychoactive Substance Market Status by Countries
 - 8.1.1 Latin America New Psychoactive Substance Sales by Countries (2016-2021)
 - 8.1.2 Latin America New Psychoactive Substance Revenue by Countries (2016-2021)
 - 8.1.3 Brazil New Psychoactive Substance Market Status (2016-2021)
 - 8.1.4 Argentina New Psychoactive Substance Market Status (2016-2021)
 - 8.1.5 Colombia New Psychoactive Substance Market Status (2016-2021)
- 8.2 Latin America New Psychoactive Substance Market Status by Manufacturers
- 8.3 Latin America New Psychoactive Substance Market Status by Type (2016-2021)
 - 8.3.1 Latin America New Psychoactive Substance Sales by Type (2016-2021)
 - 8.3.2 Latin America New Psychoactive Substance Revenue by Type (2016-2021)
- 8.4 Latin America New Psychoactive Substance Market Status by Downstream Industry (2016-2021)

CHAPTER 9 MIDDLE EAST AND AFRICA MARKET STATUS BY COUNTRIES, TYPE, MANUFACTURERS AND DOWNSTREAM INDUSTRY

- 9.1 Middle East and Africa New Psychoactive Substance Market Status by Countries

- 9.1.1 Middle East and Africa New Psychoactive Substance Sales by Countries (2016-2021)
- 9.1.2 Middle East and Africa New Psychoactive Substance Revenue by Countries (2016-2021)
- 9.1.3 Middle East New Psychoactive Substance Market Status (2016-2021)
- 9.1.4 Africa New Psychoactive Substance Market Status (2016-2021)
- 9.2 Middle East and Africa New Psychoactive Substance Market Status by Manufacturers
- 9.3 Middle East and Africa New Psychoactive Substance Market Status by Type (2016-2021)
 - 9.3.1 Middle East and Africa New Psychoactive Substance Sales by Type (2016-2021)
 - 9.3.2 Middle East and Africa New Psychoactive Substance Revenue by Type (2016-2021)
- 9.4 Middle East and Africa New Psychoactive Substance Market Status by Downstream Industry (2016-2021)

CHAPTER 10 MARKET DRIVING FACTOR ANALYSIS OF NEW PSYCHOACTIVE SUBSTANCE

- 10.1 Global Economy Situation and Trend Overview
- 10.2 New Psychoactive Substance Downstream Industry Situation and Trend Overview

CHAPTER 11 NEW PSYCHOACTIVE SUBSTANCE MARKET COMPETITION STATUS BY MAJOR MANUFACTURERS

- 11.1 Production Volume of New Psychoactive Substance by Major Manufacturers
- 11.2 Production Value of New Psychoactive Substance by Major Manufacturers
- 11.3 Basic Information of New Psychoactive Substance by Major Manufacturers
 - 11.3.1 Headquarters Location and Established Time of New Psychoactive Substance Major Manufacturer
 - 11.3.2 Employees and Revenue Level of New Psychoactive Substance Major Manufacturer
- 11.4 Market Competition News and Trend
 - 11.4.1 Merger, Consolidation or Acquisition News
 - 11.4.2 Investment or Disinvestment News
 - 11.4.3 New Product Development and Launch

CHAPTER 12 NEW PSYCHOACTIVE SUBSTANCE MAJOR MANUFACTURERS INTRODUCTION AND MARKET DATA

12.1 Zynerba Pharmaceuticals

12.1.1 Company profile

12.1.2 Representative New Psychoactive Substance Product

12.1.3 New Psychoactive Substance Sales, Revenue, Price and Gross Margin of Zynerba Pharmaceuticals

12.2 GW Pharmaceuticals

12.2.1 Company profile

12.2.2 Representative New Psychoactive Substance Product

12.2.3 New Psychoactive Substance Sales, Revenue, Price and Gross Margin of GW Pharmaceuticals

12.3 Teewinot Life Sciences

12.3.1 Company profile

12.3.2 Representative New Psychoactive Substance Product

12.3.3 New Psychoactive Substance Sales, Revenue, Price and Gross Margin of Teewinot Life Sciences

12.4 AusCann

12.4.1 Company profile

12.4.2 Representative New Psychoactive Substance Product

12.4.3 New Psychoactive Substance Sales, Revenue, Price and Gross Margin of AusCann

12.5 Cannabics Pharmaceuticals

12.5.1 Company profile

12.5.2 Representative New Psychoactive Substance Product

12.5.3 New Psychoactive Substance Sales, Revenue, Price and Gross Margin of Cannabics Pharmaceuticals

12.6 Tilray

12.6.1 Company profile

12.6.2 Representative New Psychoactive Substance Product

12.6.3 New Psychoactive Substance Sales, Revenue, Price and Gross Margin of Tilray

12.7 Cyrelion

12.7.1 Company profile

12.7.2 Representative New Psychoactive Substance Product

12.7.3 New Psychoactive Substance Sales, Revenue, Price and Gross Margin of Cyrelion

12.8 Anandia Laboratories

12.8.1 Company profile

12.8.2 Representative New Psychoactive Substance Product

12.8.3 New Psychoactive Substance Sales, Revenue, Price and Gross Margin of Anandia Laboratories

12.9 InMed Pharmaceuticals

12.9.1 Company profile

12.9.2 Representative New Psychoactive Substance Product

12.9.3 New Psychoactive Substance Sales, Revenue, Price and Gross Margin of InMed Pharmaceuticals

12.10 Renew Biopharma

12.10.1 Company profile

12.10.2 Representative New Psychoactive Substance Product

12.10.3 New Psychoactive Substance Sales, Revenue, Price and Gross Margin of Renew Biopharma

12.11 Cronos Group

12.11.1 Company profile

12.11.2 Representative New Psychoactive Substance Product

12.11.3 New Psychoactive Substance Sales, Revenue, Price and Gross Margin of Cronos Group

12.12 ICC International Cannabis

12.12.1 Company profile

12.12.2 Representative New Psychoactive Substance Product

12.12.3 New Psychoactive Substance Sales, Revenue, Price and Gross Margin of ICC International Cannabis

12.13 Biotii Technologies

12.13.1 Company profile

12.13.2 Representative New Psychoactive Substance Product

12.13.3 New Psychoactive Substance Sales, Revenue, Price and Gross Margin of Biotii Technologies

CHAPTER 13 UPSTREAM AND DOWNSTREAM MARKET ANALYSIS OF NEW PSYCHOACTIVE SUBSTANCE

13.1 Industry Chain of New Psychoactive Substance

13.2 Upstream Market and Representative Companies Analysis

13.3 Downstream Market and Representative Companies Analysis

CHAPTER 14 COST AND GROSS MARGIN ANALYSIS OF NEW PSYCHOACTIVE SUBSTANCE

14.1 Cost Structure Analysis of New Psychoactive Substance

- 14.2 Raw Materials Cost Analysis of New Psychoactive Substance
- 14.3 Labor Cost Analysis of New Psychoactive Substance
- 14.4 Manufacturing Expenses Analysis of New Psychoactive Substance

CHAPTER 15 REPORT CONCLUSION

CHAPTER 16 RESEARCH METHODOLOGY AND REFERENCE

- 16.1 Methodology/Research Approach
 - 16.1.1 Research Programs/Design
 - 16.1.2 Market Size Estimation
 - 16.1.3 Market Breakdown and Data Triangulation
- 16.2 Data Source
 - 16.2.1 Secondary Sources
 - 16.2.2 Primary Sources
- 16.3 Reference

I would like to order

Product name: New Psychoactive Substance-Global Market Status & Trend Report 2016-2026 Top 20 Countries Data

Product link: <https://marketpublishers.com/r/N37B07BDA2CDEN.html>

Price: US\$ 3,680.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/N37B07BDA2CDEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

